Global Blood Therapeutics

Global Blood Therapeutics

Based: San Francisco
Raised: $40.7 million
Investors: Third Rock, undisclosed

The scoop: Third Rock weighed in to launch this biotech on the West Coast, where it's been making steady inroads after establishing itself as a major presence in Boston. San Francisco-based startup Global Blood Therapeutics is planning to develop a pipeline of oral drugs, with the lead program targeting sickle cell disease. Its investigators will use a tech platform dubbed SHAPE to tweak the shapes of key blood proteins in order to treat chronic blood-based diseases and genetic disorders. And the biotech plans to bring together expertise in computational biology, protein-ligand modeling with medicinal chemistry and "empiric screening capabilities focused on allosteric modulation." Third Rock partner Mark Goldsmith, who headed the startup team at Constellation, is taking the helm of the the new company. And he'll be joined by an experienced cast of drug developers, including Charles Homcy, who helped found Portola.

Global Blood Therapeutics

Suggested Articles

Nearly 80% of clinical trials fail to meet their activation timelines. But why does the start-up process fail us this often? Read the article to learn

Medimmune’s Ronald Herbst, Ph.D., has followed a series of other AstraZeneca and its biologics arm staffers out the door.

The takeover will give Alexion two clinical-phase medicines in development in complement alternative pathway-mediated rare diseases.